251 related articles for article (PubMed ID: 33966917)
21. Acute cellular rejection in hepatitis C recipients following liver transplantation in the era of direct-acting antivirals: chronological analysis of the United Network for Organ Sharing database.
Tanaka T; Voigt MD
J Hepatobiliary Pancreat Sci; 2019 Sep; 26(9):393-400. PubMed ID: 31211912
[TBL] [Abstract][Full Text] [Related]
22. Therapy With Direct-Acting Antiviral Agents for Hepatitis C in Liver Transplant Recipients.
Nogueras López F; López Garrido A; Ortega Suazo EJ; Vadillo Calles F; Valverde López F; Espinosa Aguilar MD
Transplant Proc; 2018 Mar; 50(2):631-633. PubMed ID: 29579872
[TBL] [Abstract][Full Text] [Related]
23. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
[TBL] [Abstract][Full Text] [Related]
24. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V
AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.
Crespo G; Trota N; Londoño MC; Mauro E; Baliellas C; Castells L; Castellote J; Tort J; Forns X; Navasa M
J Hepatol; 2018 Jul; 69(1):11-17. PubMed ID: 29481821
[TBL] [Abstract][Full Text] [Related]
26. Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting.
Pischke S; Polywka S; Proske VM; Lang M; Jordan S; Nashan B; Lohse AW; Sterneck M
Transpl Infect Dis; 2016 Feb; 18(1):141-5. PubMed ID: 26485543
[TBL] [Abstract][Full Text] [Related]
27. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study.
Gorgen A; Galvin Z; Huang AC; Vinaixa C; O'Rourke JM; Francoz C; Hansen BE; Durand F; Elsharkawy AM; Shah T; Berenguer M; Rubin A; Calatayud D; Mehta N; Terrault NA; Lilly LB; Selzner N; Sapisochin G
Transplantation; 2020 Oct; 104(10):2087-2096. PubMed ID: 31978002
[TBL] [Abstract][Full Text] [Related]
28. Current management and perspectives for HCV recurrence after liver transplantation.
Coilly A; Roche B; Samuel D
Liver Int; 2013 Feb; 33 Suppl 1():56-62. PubMed ID: 23286847
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents?
Dall'Agata M; Gramenzi A; Biselli M; Bernardi M
World J Gastroenterol; 2014 Jul; 20(28):9253-60. PubMed ID: 25071318
[TBL] [Abstract][Full Text] [Related]
30. Perspectives on treating hepatitis C infection in the liver transplantation setting.
Chen T; Terrault NA
Curr Opin Organ Transplant; 2016 Apr; 21(2):111-9. PubMed ID: 26927201
[TBL] [Abstract][Full Text] [Related]
31. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
Aqel B; Leise M; Vargas HE; Watt KD; Keaveny AP; Zhang N; Zhang N; Pungpapong S
Ann Hepatol; 2018 Aug; 17(5):815-821. PubMed ID: 30145562
[TBL] [Abstract][Full Text] [Related]
32. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
[TBL] [Abstract][Full Text] [Related]
33. Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras.
Jacob JS; Shaikh A; Goli K; Rich NE; Benhammou JN; Ahmed A; Kim D; Rana A; Goss JA; Naggie S; Lee TH; Kanwal F; Cholankeril G
Clin Infect Dis; 2023 Feb; 76(4):592-599. PubMed ID: 36221143
[TBL] [Abstract][Full Text] [Related]
34. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
Lim KB; Sima HR; Fiel MI; Khaitova V; Doucette JT; Chernyiak M; Ahmad J; Bach N; Chang C; Grewal P; Kim-Schluger L; Liu L; Odin J; Perumalswami P; Florman SS; Schiano TD
World J Gastroenterol; 2015 May; 21(20):6236-45. PubMed ID: 26034358
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.
Vitale A; Spolverato G; Burra P; De Feo TM; Belli L; Donato F; Baroni GS; Marianelli T; Picciotto A; Toniutto P; Bhoori S; Passigato N; Lucà MG; Russo FP; Cillo U; Fagiuoli S;
Transpl Int; 2015 Sep; 28(9):1055-65. PubMed ID: 25865602
[TBL] [Abstract][Full Text] [Related]
36. Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.
Donato MF; Morelli C; Romagnoli R; Invernizzi F; Mazzarelli C; Iemmolo RM; Montalbano M; Lenci I; Bhoori S; Pieri G; Berardi S; Caraceni P; Martini S;
Liver Int; 2017 May; 37(5):678-683. PubMed ID: 27865034
[TBL] [Abstract][Full Text] [Related]
37. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
Pillai AA; Wedd J; Norvell JP; Parekh S; Cheng N; Young N; Spivey JR; Ford R
Am J Gastroenterol; 2016 Feb; 111(2):250-60. PubMed ID: 26832650
[TBL] [Abstract][Full Text] [Related]
38. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States.
Young K; Liu B; Bhuket T; Gish RG; Wong RJ
J Viral Hepat; 2019 Mar; 26(3):350-361. PubMed ID: 30412318
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Follow-up of Liver Transplant Recipients Treated With Direct-Acting Antiviral Agents for Hepatitis C Recurrence After Transplantation.
Cieciura T; Hryniewiecka E; Foroncewicz B; Strzelczyk Z; Ciszek M; Paczek L
Transplant Proc; 2020 Oct; 52(8):2468-2471. PubMed ID: 32241638
[TBL] [Abstract][Full Text] [Related]
40. Indication for Liver Transplantation After Direct-Acting Agents in the Treatment of Patients With Hepatitis C.
Arias ABV; Villegas Herrera MT; Arco Sánchez A; Adel ME; Triguero Cabrera J; Plata Illescas C; Montes Osuna MC; Santoyo Villalba J; Villar Del Moral JM
Transplant Proc; 2022; 54(1):32-34. PubMed ID: 34911619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
